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OBJECTIVES: Many employers provide ﬁnancial incentives for
enrollees to switch to mail order pharmacies from retail phar-
macies and to lower-cost generic drugs. We assess the effects of
the introduction of an incentive-based formulary on maintenance
prescription drug utilization for early retirees with chronic con-
ditions. METHODS: We take advantage of a natural experiment
where one employer introduced an incentive-based formulary
and a comparison employer that did not change copayments. A
monthly panel data set was created from the 1996–1997 Mar-
ketScan database representing the maintenance prescription drug
experience for continuously-enrolled early retirees and spouses
with at least one chronic condition (n = 6165). Negative bino-
mial difference-in-difference models were estimated to measure
the effects of the beneﬁt change. Distributed lag models were esti-
mated to assess the extent of pre-implementation stockpiling of
prescription drugs. RESULTS: Utilization of maintenance pre-
scription drugs declined 5.5% (p < 0.01) after the introduction
of an incentive-based prescription drug beneﬁt, a decline that
was limited to retail pharmacy prescriptions. In contrast, mail
order utilization rose 23% (p < 0.001), dominated by an increase
in mail order brand name prescriptions (31%, p < 0.001). There
was little evidence of generic substitution as the utilization 
of generic drugs ﬁlled in a retail pharmacy dropped 8.9% (p =
0.001) and mail order generic prescriptions were largely
unchanged. No evidence of pre-implementation stockpiling of
brand name retail drugs was discovered, although enrollees may
have anticipated the change and increased utilization of mail
order brand name and retail generic drugs in the two months
prior to the new beneﬁt. CONCLUSIONS: The introduction of
an incentive-based formulary had signiﬁcant effects on mainte-
nance drug utilization patterns for early retirees with chronic
conditions, a subgroup that typically depends upon prescription
drugs to maintain and improve health. Contrary to expectations,
generic drug use did not increase. However, many enrollees
switched to mail order pharmacy for brand name drugs.
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COX-2 INHIBITOR STEP CARE PROGRAM ON MEDICATION
COSTS AND UTILIZATION: RESULTS FROM A PHARMACY
BENEFIT MANAGEMENT SETTING
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Bertram C
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OBJECTIVES: COX-2 Inhibitor Step Care program is designed
to promote the use of traditional NSAIDs as a ﬁrst line agent
before a COX-2 inhibitor is used. This study evaluated the
impact of this program on COX-2 inhibitor utilization and
expenditures in a pharmacy beneﬁt management organization.
METHODS: Using pre-post with control group study design,
prescription records from January 1, 2003 to October 31, 2004
were obtained from Walgreens Health Initiatives’ pharmacy
claims database. The study group comprised of three employer
groups enrolled in COX-2 Step Care in September 2003, while
the control group comprised of all other clients not enrolled in
the program. Number of prescriptions dispensed and total costs
per member per month (PMPM) were analyzed. PMPM cost
savings were calculated using formula: Y¢ = Yst0 *Rct-Yst1, where
st0 and st1 represent actual pre and post PMPM total costs in study
group and Rct is the ratio of PMPM pre and post total costs in
control group. RESULTS: The study group included 166,719
lives, and the control group included 768,836 lives from 227
clients. From the pre to post period, in the study group, the
average number of prescriptions per month and the average
PMPM costs decreased by 4.7% (from 1842 to 1755) and 8.7%
(from $1.38 to $1.26) respectively. In the control group,
however, the average number of prescriptions and the average
PMPM costs increased by 42.5% (from 9034 to 12,875) and
16.5% (from $1.62 to $1.89). After comparing the trend of
COX-2 inhibitors in these two groups, COX-2 Step Care was
estimated to result in $0.35 PMPM and $700,220 annualized
cost savings for the three employer groups. CONCLUSIONS:
COX-2 Step Care led to a decrease of prescription utilization and
savings in PMPM total costs and may be an effective option in
controlling prescription drug expenditures.
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OBJECTIVE: Cost-effectiveness analyses based on clinical trials,
using life-years gained (LYG) or QALY as endpoints require sur-
vival estimates, which must account for event patterns and sur-
vival during the trial and patient characteristics. METHODS:
Using data from Saskatchewan Health, two statistical ap-
proaches were developed to estimate the full survival curves
applicable to patients in the CURE trial, categorized into: “sur-
vived with no further events”, “survived after myocardial infarc-
tion (MI)”, “survived after stroke”, “died”. One approach
involved ﬁtting four piecewise parametric functions per category
to hazards observed in 15,590 patients with index MI (64%
male, mean age 69 years, half died during ten-years follow-up).
The other was to ﬁt a single equation using fractional polyno-
mials. Time-dependent Cox proportional hazards analyses were
used to derive individual risk-adjustment scores. Resulting sur-
vival curves were integrated to obtain life expectancy (LE); LYG
by avoiding non-fatal events were derived by subtracting event-
speciﬁc LE from that of no events for each patient type.
RESULTS: Patients (24% diabetic; 30% previous MI/stroke;
61% hypertensive) in ﬁrst nine-months (corresponding to trial),
suffered non-fatal MI (5%); non-fatal stroke (1%); 72% event-
free. Both types of hazard functions indicate high risk immedi-
ately following index MI, dropping sharply with event-free time.
Subsequent events renew the risk. Integrating survival curves
yields estimates of impact of preventing events: e.g., 65 year-old,
diabetic, hypertensive man with no previous events has LE = 7.98
years immediately after MI. This increases to 9.4 years if he sur-
vives through nine-months with no further events; 3.62 years are
lost with second MI, 5.08 years with a stroke. CONCLUSION:
These techniques yield detailed survival functions enabling
extensive customization to obtain life-years lost for any pattern
of events in any given patient. A second event, even if not imme-
diately fatal, further reduces life-expectancy and must be con-
sidered in economic analyses.
